The Biochemical and Clinical Consequences of 2′-Deoxycoformycin in T Cell Chronic Lymphocytic Leukaemia
- 24 April 2009
- journal article
- research article
- Published by Wiley in Scandinavian Journal of Haematology
- Vol. 32 (1) , 55-64
- https://doi.org/10.1111/j.1600-0609.1984.tb00678.x
Abstract
The mechanisms for cell toxicity with adenosine deaminase inhibition by 2''-deoxycoformycin (dCF) in nonreplicating lymphoid cells include S-adenosylhomocysteine (SAH) hydrolase inactivation and reduction of cellular ATP content. These postulates were explored in a patient with T-CLL [T cell chronic lymphocytic leukemia] receiving dCF with a resultant fall in peripheral blood lymphocytes from 740 .times. 109/l to 90 .times. 109/l over 15 days. In red blood cells there was complete inhibition of adenosine deaminase and SAH hydrolase activities, progressive dATP accumulation and ATP depletion, but no significant alteration in AMP deaminase activity or distribution in purine intermediates from radioactive adenosine. In T-CLL lymphocytes there was incomplete lymphoid SAH hydrolase inactivation, reduced AMP deaminase activity and progressive dATP accumulation. The limited decrease in lymphocyte ATP content was related more to dCF administration than dATP accumulation, and was not accompanied by significant changes in the distribution of purine intermediates from adenosine. ATP depletion with dCF therapy probably does not reflect AMP deaminase activity modulation and probably is not of critical importance for cell toxicity. The exact role for elevated cellular dATP content and SAH hydrolase inactivation in this toxicity remains to be established.Keywords
This publication has 34 references indexed in Scilit:
- Deoxycoformycin-induced response in chronic lymphocytic leukaemia: deoxyadenosine toxicity in non-replicating lymphocytesBritish Journal of Haematology, 1982
- THERAPEUTIC SELECTIVITY OF AND PREDICTION OF RESPONSE TO 2'-DEOXYCOFORMYCIN IN ACUTE LEUKAEMIAThe Lancet, 1981
- Studies on the Biochemical Sequelae of Therapy in Thy-Acute Lymphoblastic Leukaemia with the Adenosine Deaminase Inhibitor 2’DeoxycoformycinBritish Journal of Haematology, 1981
- Adenosine kinase from human erythrocytes: determination of the conditions required for assay in crude hemolysatesClinica Chimica Acta; International Journal of Clinical Chemistry, 1980
- Adenylate deaminase: Potent inhibition by 2′-deoxycoformycin 5′-phosphateBiochemical and Biophysical Research Communications, 1979
- Reduction of RibonucleotidesAnnual Review of Biochemistry, 1979
- A micromethod for determining adenosine deaminase and purine nucleoside phosphorylase activity in cells from human peripheral bloodClinica Chimica Acta; International Journal of Clinical Chemistry, 1978
- Role of S-adenosylhomocysteine in adenosine-mediated toxicity in cultured mouse T lymphoma cellsCell, 1977
- Deoxyribonucleoside Triphosphates in Human Cells: Changes in Disease and Following Exposure to DrugsEuropean Journal of Clinical Investigation, 1975
- ADENOSINE-DEAMINASE DEFICIENCY IN TWO PATIENTS WITH SEVERELY IMPAIRED CELLULAR IMMUNITYThe Lancet, 1972